Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 381, Issue 4, 2010, Pages 361-370

  Biala, Grazyna ^a   Staniak, Natasza ^a   Budzynska, Barbara ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Mecamylamine; Morphine; Nicotine; Place conditioning; Rats; Varenicline

Indexed keywords

MECAMYLAMINE; MORPHINE; NICOTINE; NICOTINIC RECEPTOR ALPHA4BETA2; VARENICLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC ACTIVITY; CONDITIONING; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; EXPERIMENTAL RAT; LIGAND BINDING; MALE; NONHUMAN; PLACE PREFERENCE; RAT; RELAPSE; TOBACCO DEPENDENCE;

ANIMALS; BENZAZEPINES; CONDITIONING, CLASSICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MECAMYLAMINE; MORPHINE; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; QUINOXALINES; RATS; RATS, WISTAR; RECEPTORS, NICOTINIC; REWARD; TOBACCO USE DISORDER;

EID: 77953230225     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-010-0498-5     Document Type: Article

References (48)

1. LE Almeida EF Pereira M Alkondon WP Fawcett WR Randall EX Albuquerque 2000 The opioid antagonist naltrexone inhibits activity and alters expression of alpha7 and alpha4beta2 nicotinic receptors in hippocampal neurons: implications for smoking cessation programs Neuropharmacology 39 2740 2755 10.1016/S0028-3908(00)00157-X 1:CAS:528:DC%2BD3cXntlGqsbg%3D 11044744
2. DJ Balfour 2002 Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence Curr Drug Targets CNS Neurol Disord 1 413 421 10.2174/1568007023339076 1:CAS:528:DC%2BD38XlsFSmsrs%3D 12769613
3. F Berrendero BL Kieffer R Maldonado 2002 Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in μ-opioid receptor knock-out mice J Neurosci 22 10935 10940 1:CAS:528:DC%2BD38XpslCqtLg%3D 12486188
4. G Biala 2003 Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents Pol J Pharmacol 55 327 335 1:CAS:528:DC%2BD3sXotlemtbg%3D 14506311
5. G Biala B Budzynska 2006 Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists Eur J Pharmacol 537 85 93 10.1016/j.ejphar.2006.03.017 1:CAS:528:DC%2BD28XktVegtLk%3D 16616917
6. G Biala B Weglinska 2006 On the mechanism of cross-tolerance between morphine- and nicotine-induced antinociception: involvement of calcium channels Prog Neuropsychopharmacol Biol Psychiatry 30 15 21 10.1016/j.pnpbp.2005.04.021 1:CAS:528:DC%2BD2MXhtlGls7vN 16202496 (Pubitemid 43021318)
7. G Biala B Budzynska 2008 Calcium-dependent mechanisms of the reinstatement of nicotine-conditioned place preference by drug priming in rats Pharmacol Biochem Behav 89 116 125 10.1016/j.pbb.2007.12.005 1:CAS:528:DC%2BD1cXovFGqsw%3D%3D 18178244
8. G Biala B Budzynska M Kruk 2005 Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice Pharmacol Rep 57 755 760 1:CAS:528:DC%2BD28XjtlCks74%3D 16382193
9. DJ Calcagnetti MD Schechter 1994 Nicotine place preference using the biased method of conditioning Prog Neuropsychopharmacol Biol Psychiatry 18 925 933 10.1016/0278-5846(94)90108-2 1:CAS:528:DyaK2cXmt1Wkuro%3D 7972862 (Pubitemid 24234875)
10. Carr GD, Fibiger HC, Phillips AG (1989) Conditioned place preference as a measure of drug reward. In: Liebman JM, Cooper SJ (eds) The neuropharmacological basis of reward. Oxford University Press, Oxford, pp 264-319
11. N Chaudhri AR Caggiula EC Donny S Booth M Gharib L Craven, et al. 2006 Operant responding for conditioned and unconditioned reinforcers in rats is differentially enhanced by the primary reinforcing and reinforcement-enhancing effects of nicotine Psychopharmacology 189 27 36 10.1007/s00213-006-0522-0 1:CAS:528:DC%2BD28XhtV2rs7jI 17019569 (Pubitemid 44607257)
12. JW Coe PR Brooks MG Vetelino MC Wirtz EP Arnold J Huang, et al. 2005 Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation J Med Chem 48 3474 3477 10.1021/jm050069n 1:CAS:528: DC%2BD2MXjsFyjtb4%3D 15887955 (Pubitemid 40664098)
13. C Cohen OE Bergis F Galli AW Lochead S Jegham B Biton, et al. 2003 SSR591813, a novel and selective partial a4b2 nicotinic receptor with potential as an aid for smoking cessation J Pharmacol Exp Ther 306 407 420 10.1124/jpet.103.049262 1:CAS:528:DC%2BD3sXkvF2ks7g%3D 12682217 (Pubitemid 36734399)
14. WA Corrigall KB Franklin KM Coen PB Clarke 1992 The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine Psychopharmacology 107 285 289 10.1007/BF02245149 1:CAS:528:DyaK38XktVamu7c%3D 1615127
15. JA Dani D Ji FM Zhou 2001 Synaptic plasticity and nicotine addiction Neuron 31 349 352 10.1016/S0896-6273(01)00379-8 1:CAS:528:DC%2BD3MXmsVeju70%3D 11516393 (Pubitemid 32778555)
16. EC Donny AR Caggiula MM Mielke S Booth MA Gharib A Hoffman, et al. 1999 Nicotine self-administration in rats on a progressive ratio schedule of reinforcement Psychopharmacology (Berl) 147 135 142 10.1007/s002130051153 1:CAS:528:DC%2BD3cXpslKltA%3D%3D
17. M Ericson E Löf R Stomberg B Söderpalm 2009 The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rats mesolimbic dopamine system JPET 329 225 230 10.1124/jpet.108.147058 1:CAS:528:DC%2BD1MXksVKnu70%3D
18. M Fiserova S Consolo M Krsiak 1999 Chronic morphine induces long-lasting changes in acetylcholine release in rat nucleus accumbens core and shell: an in vivo microdialysis study Psychopharmacology 142 85 94 10.1007/s002130050866 1:CAS:528:DyaK1MXitVChurg%3D 10102787 (Pubitemid 29196068)
19. C Gotti F Clementi 2004 Neuronal nicotinic receptors: from structure to pathology Prog Neurobiol 74 363 396 10.1016/j.pneurobio.2004.09.006 1:CAS:528:DC%2BD2MXksVertA%3D%3D 15649582 (Pubitemid 40092737)
20. B Gronier KW Perry K Rasmussen 2000 Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area Psychopharmacology 147 347 355 10.1007/s002130050002 1:CAS:528:DC%2BD3cXhsVOhtrg%3D 10672627
21. JR Hughes 2007 Effects of abstinence from tobacco: valid symptoms and time course Nicotine Tob Res 9 315 327 10.1080/14622200701188919 17365764 (Pubitemid 46404264)
22. AE Kelley 2002 Nicotinic receptors: addiction's smoking gun? Nat Med 8 447 449 10.1038/nm0502-447 1:CAS:528:DC%2BD38Xjt1KgtLk%3D 11984581 (Pubitemid 34546740)
23. SL Kenford MC Fiore DE Jorenby SS Smith D Wetter TB Baker 1994 Predicting smoking cessation. Who will quit with and without the nicotine patch JAMA 271 589 594 10.1001/jama.271.8.589 1:STN:280:DyaK2c7jtlerug%3D%3D 8301790 (Pubitemid 24061691)
24. HD Mansvelder JR Keath DS McGehee 2002 Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas Neuron 33 905 919 10.1016/S0896-6273(02)00625-6 1:CAS:528:DC%2BD38Xis1Wrtr8%3D 11906697 (Pubitemid 34246356)
25. MJ Marks JR Pauly SD Gross ES Deneris I Hermans-Borgmeyer SF Heinemann AC Collins 1992 Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment J Neurosci 12 2765 2784 1:CAS:528:DyaK38XltVKiu7o%3D 1613557
26. LM Marubio AM Gardier S Durier D David R Klink MM Arroyo-Jimenez, et al. 2003 Effects of nicotine in the dopaminergic system of mice lacking the alpha 4 subunit of neuronal nicotinic acetylcholine receptors Eur J Neurosci 17 1327 1337 10.1046/j.1460-9568.2003.02564.x (Pubitemid 36560833)
27. U Maskos BE Molles S Pons M Besson BP Guiard J-P Guilloux, et al. 2005 Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors Nature 436 103 107 10.1038/nature03694 1:CAS:528: DC%2BD2MXlvVGiu7o%3D 16001069 (Pubitemid 40966193)
28. AD Miller GL Forster JS Yeomans CD Blaha 2005 Midbrain muscarinic receptors modulate morphine-induced accumbal and striatal dopamine efflux in the rat Neuroscience 136 531 538 10.1016/j.neuroscience.2005.08.035 1:CAS:528:DC%2BD2MXht1SqtrrJ 16216430 (Pubitemid 41607901)
29. MR Picciotto M Zoli R Rimondini C Lena LM Marubio E Merlo-Pich, et al. 1998 Acetylcholine receptors containing the beta-2 subunit are involved in the reinforcing properties of nicotine Nature 391 173 177 10.1038/34413 1:CAS:528:DyaK1cXmt1WrsA%3D%3D 9428762 (Pubitemid 28092475)
30. LA Potts CL Garwood 2007 Varenicline: the newest agent for smoking cessation Am J Health-Syst Pharm 64 1381 1384 10.2146/ajhp060428 1:CAS:528:DC%2BD2sXotV2mtLw%3D 17592002 (Pubitemid 47025536)
31. S Rahman NM Neugebauer Z Zhang PA Crooks LP Dwoskin MT Bardo 2007 The effects of a novel nicotinic receptor antagonist N, Ndodecane-1, 12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens Neuropharmacology 52 755 763 10.1016/j.neuropharm.2006.09.012 1:CAS:528:DC%2BD2sXhvVyqtrY%3D 17097117 (Pubitemid 46227466)
32. MS Reid L Fox LB Ho SP Berger 2000 Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: neuropharmacological characterization Synapse 35 129 136 10.1002/(SICI)1098-2396(200002)35:2<129::AID-SYN5>3.0. CO;2-D 1:CAS:528:DC%2BD3cXkt1SktA%3D%3D 10611638 (Pubitemid 30036189)
33. A Rezayof F Nazari-Serenjeh MR Zarrindast H Sepehri L Delphi 2007 Morphine-induced place preference: involvement of cholinergic receptors of the ventral tegmental area Eur J Pharmacol 562 92 102 10.1016/j.ejphar.2007.01.081 1:CAS:528:DC%2BD2sXjslSkt74%3D 17336285 (Pubitemid 46466767)
34. H Rollema JW Coe LK Chambers RS Hurst SM Stahl KE Williams 2007 Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation Trends Pharmacol Sci 28 316 325 10.1016/j.tips.2007.05.003 1:CAS:528:DC%2BD2sXnsFKnsr0%3D 17573127 (Pubitemid 47016686)
35. H Rollema LK Chambers JW Coe J Glowa RS Hurst LA Lebel, et al. 2007 Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Neuropharmacology 52 985 994 10.1016/j.neuropharm.2006.10.016 1:CAS:528:DC%2BD2sXhvVyqtbw%3D 17157884 (Pubitemid 46227486)
36. JA Stapleton L Watson LI Spirling R Smith A Milbrandt M Ratcliffe G Sutherland 2008 Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness Addiction 103 146 154 10.1111/j.1360-0443.2007.02083.x 18028247 (Pubitemid 350233424)
37. K Taguchi Y Hagiwara Y Suzuki T Kubo 1993 Effects of morphine on release of acetylcholine in the rat striatum: an in vivo microdialysis study Naunyn Schmiedebergs Arch Pharmacol 347 9 13 10.1007/BF00168765 1:CAS:528: DyaK3sXhs1Sqt7s%3D 8095326
38. AR Tome V Izaguirre LM Rosario V Cena G Gonzales-Garcia 2001 Naloxone inhibits nicotine-induced receptor current and catecholamine secretion in bovine chromaffin cells Brain Res 903 62 65 10.1016/S0006-8993(01)02388-5 1:CAS:528:DC%2BD3MXjvV2rtbc%3D 11382388 (Pubitemid 32904607)
39. S Tonstad P Tønnesen P Hajek KE Williams CB Billing KR Reeves 2006 Varenicline Phase 3 Study Group. Effect of establishment therapy with varenicline on smoking cessation: a randomized controlled trial JAMA 296 64 71 10.1001/jama.296.1.64 1:CAS:528:DC%2BD28Xms1OrtLo%3D 16820548
40. TM Tzschentke 1998 Measuring reward with the conditioned place preference paradigm: a comparative review of drug effects, recent progress and new issues Prog Neurobiol 56 613 672 10.1016/S0301-0082(98)00060-4 1:CAS:528: DyaK1MXitVSqsQ%3D%3D 9871940 (Pubitemid 29012461)
41. SS Watkins MP Epping-Jordan GF Koob A Markou 1999 Blockade of nicotine self-administration with nicotinic antagonists in rats Pharmacol Biochem Behav 62 743 751 10.1016/S0091-3057(98)00226-3 1:CAS:528:DyaK1MXitVCgsLw%3D 10208381 (Pubitemid 29127180)
42. R West M Ussher M Evans M Rashid 2006 Assessing DSM-IV nicotine withdrawal symptoms: a comparison and evaluation of five different scales Psychopharmacology 184 619 627 10.1007/s00213-005-0216-z 1:CAS:528: DC%2BD28XhsFCltr0%3D 16308727 (Pubitemid 43255878)
43. S Wonnacott 1997 Presynaptic nicotinic ACh receptors Trends Neurosci 20 92 98 10.1016/S0166-2236(96)10073-4 1:CAS:528:DyaK2sXhtFajtrk%3D 9023878 (Pubitemid 27050704)
44. S Wonnacott N Sidhpura DJ Balfour 1997 Nicotine: from molecular mechanisms to behaviour Curr Opin Pharmacol 5 53 59 10.1016/j.coph.2004.12.002
45. JR Wooltorton VI Pidoplichko RS Broide JA Dani 2003 Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas J Neurosci 23 3176 3185 1:CAS:528:DC%2BD3sXjsFSksbw%3D 12716925
46. J Yeomans M Baptista 1997 Both nicotinic and muscarinic receptors in ventral tegmental area contribute to brain-stimulation reward Pharmacol Biochem Behav 57 915 921 10.1016/S0091-3057(96)00467-4 1:CAS:528:DyaK2sXlt1WrtLk%3D 9259024 (Pubitemid 27334444)
47. J Yeomans A Mathur M Tampakeras 1993 Rewarding brain stimulation: role of tegmental cholinergic neurons that activate dopamine neurons Behav Neurosci 107 1077 1087 10.1037/0735-7044.107.6.1077 1:STN:280:DyaK2c7otlCmsA%3D%3D 8136061 (Pubitemid 24018218)
48. MR Zarrindast MR Khoshayand B Shafaghi 1999 The development of cross-tolerance between morphine and nicotine in mice Eur Neuropsychopharmacol 9 227 233 10.1016/S0924-977X(98)00030-3 1:CAS:528:DyaK1MXhsVWntLg%3D 10208292 (Pubitemid 29114928)